Category Archives: Stem Cell Treatment


New Comprehensive Report on Stem Cell Therapy Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like Chiesi Pharmaceuticals,…

The Stem Cell TherapyIndustry study now available at Grand View Report, is a detailed sketch of the business sphere in terms of current and future trends driving the profit matrix. The report also indicates a pointwise outline of market share, market size, industry partakers, and regional landscape along with statistics, diagrams, & charts elucidating various noteworthy parameters of the industry landscape.

The Stem Cell Therapy Market research report offers an exhaustive analysis of this business space. The key trends that define the Stem Cell TherapyIndustry market during the analysis timeframe are mentioned in the report, alongside other factors such as regional scope and regulatory outlook. Also, the document elaborates on the impact of current industry trends on key market driving factors as well as top challenges.

Request a sample Report of Stem Cell TherapyIndustry Market at:https://grandviewreport.com/sample/21697

Top Key Players Profiled in This Report: , Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

The study also provides with a summary of the competitive spectrum as well as an in-depth assessment of the raw materials and downstream buyers.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

Our study helps to acquire the following:

Elaborating on the competitive landscape of Stem Cell TherapyIndustry market:

A gist of the regional scope of the Stem Cell TherapyIndustry market:

Ask for Discount on Stem Cell TherapyIndustry Market Report at:https://grandviewreport.com/discount/21697

Other information mentioned in the Stem Cell TherapyIndustry market report:

The report answers important questions that companies may have when operating in the global Stem Cell TherapyIndustry market. Some of the questions are given below:

For More Details On this Report:https://grandviewreport.com/industry-growth/Stem-Cell-Therapy-Market-21697

See the article here:
New Comprehensive Report on Stem Cell Therapy Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like Chiesi Pharmaceuticals,...

Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL – OncLive

Selinexor (Xpovio) may serve as a favorable therapeutic option for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for intensive chemotherapy or CAR T-cell therapy, according to Brian T. Hill, MD, PhD, who added that the agent is now being explored in combination as well as in earlier lines of treatment.

In June 2020, the FDA approved selinexor for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, following at least 2 lines of systemic therapy.

The regulatory decision was based on data from the phase 2b SADAL trial(NCT02227251),in which the agent elicited a 29% overall response rate (ORR; 95% CI, 22-38) in a total of 129 patients with DLBCL after 2 to 5 systemic regimens; this included a complete response rate of 13%. Notably, 38% of patients who achieved a partial response or CR had response durations of at least 6 months; 15% had response durations that persisted for at least 12 months. These responses were encouraging, noted Hill, especially for such a heavily pretreated population.

Selinexor is an oral agent that can potentially be taken for prolonged periods of time with adequate supportive care and monitoring for adverse effects (AEs); that's new to the field and new to this disease, said Hill. All of the effective therapies we've had previously have been exclusively intravenous or rely on intravenous therapy. Particularly for older patients who are not candidates for intensive therapy such as autologous stem cell transplant or CAR T-cell therapy, [selinexor] may represent a viable treatment strategy.

In an interview withOncLive,Hill, director of the Lymphoid Malignancies Program and a staff physician at the Cleveland Clinic Taussig Cancer Institute, shed light on XPO1 as a target in DLBCL, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

OncLive: Could you start off by describing the challenges faced in managing heavily pretreated patients with DLBCL?

Hill: After [progression on] frontline therapy, patients with DLBCL are at high risk for [additional] treatment failure and poor survival. We had autologous stem cell transplant for appropriate candidates and now we have CAR T-cell therapy, as well. However, beyond those 2 relatively intense modalities of treatment, historically, we've had very few tools to treat patients who are in a deep relapsed or refractory state.

How has treatment evolved in recent years?

The major change in the treatment of [patients with] relapsed DLBCL was introduced a couple of years ago with the FDA approval of CAR T-cell therapy. Before this modality, we really did not have any good [methods for] achieving durable remission for patients who had relapsed after autologous stem cell transplant, or for those who could never achieve sufficient disease control or have enough chemosensitivity to make it to transplant.

We're now in this postCAR T era, but the reality is that the rate of durable remission in the best of circumstances, even with CAR T-cell therapy, [ranges from approximately] 40% to 50% [of patients who go on to achieve] durable remission. That means that even with CAR T cells, over half of patients are still going to progress on their treatment. There's still an unmet need for effective therapies that can keep patients going beyond that.

Could you speak to XPO1 as a target in this disease?

XPO1 is a nuclear export protein, which shuttles various transcription factors and other regulatory proteins in and out of the cell nucleus. By inhibiting XPO1 with the selective nuclear export inhibitor selinexor, their cell undergoes apoptosis through a variety of mechanisms. This is a novel target we haven't had before in oncology.

Selinexor was recently approved by the FDA. Could you speak to thefindings from the phase 2b SADAL trialthat led to its approval?

Selinexor was previously FDA approved for use in heavily pretreated multiple myeloma and [the agent] recently gained approval for relapsed/refractory DLBCL based on findings from the SADAL trial. This [trial was done in] a heavily pretreated patient population, many of whom received multiple lines of previous therapy, including autologous stem cell transplant. In these patients, selinexor was given orally twice a week at a couple of different doses, either 100 mg or 60 mg. The toxicity seen at the high dose was significant in terms of cytopenia and gastrointestinal [AEs]. However, those AEs [were reduced when the drug was given] at the dose of 60 mg twice a week. The ORR was [around] 30%, which for a heavily pretreated patient population is very reasonable.

Is selinexor under examination in any other clinical trials?

As is frequently the case with new drug approvals, selinexor was shown to have activity in an extensively pretreated patient population. The natural progression of [research and] development is going to be to move the agent into earlier lines of treatment.

Right now, the drug is being [evaluated in] various second- and third-line platinum-based chemotherapy combinations that still have activity in DLBCL; the potential that this may be additive [in terms of] efficacy without additional toxicity is being examined, as well.

Beyond this agent, are any efforts examining XPO1 inhibition?

This target is now being explored in a wide variety of malignancies. In addition to multiple myeloma and DLBCL, [XPO1 inhibitors] now being combined with other pathway inhibitors, both for hematologic malignancies and for solid tumors.

Are any other notable agents coming down the pike that you wanted to highlight?

Just within the past year, we've had 3 drugs approved in the relapsed/refractory DLBCL setting. We have the antibody-drug conjugate polatuzumab vedotin(Polivy); the monoclonal antibody [targeted] against CD19, tafasitamab-cxix (Monjuvi), which is used in combination with lenalidomide(Revlimid); and selinexor.

[These agents are] welcome additions; [its important] to have more than 1 option [for] this patient population because it's unlikely that any of these [agents] are going to be curative. However, if were able to extend the patient's wellbeing and livelihood for a period of time following progression on curative intent therapy, [were] still clinically benefitting them.

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma. News release. FDA. June 22, 2020. Accessed August 30, 2020. bit.ly/37VnEXd.

Visit link:
Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL - OncLive

Emerging Evidence Supports the Use of Narsoplimab in HSCT-TMA – OncLive

During the 2020 European Society for Blood and Marrow Transplantation Annual Meeting, Rafael F. Duarte, MD, PhD, FRCP, of the Hospital Universitario Puerta de Hierro Majadahonda in Madrid, Spain, presented 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab (OMS721) demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).

Because the selection of patients for clinical trials has limitations, and more so, because running a trial is a hard endeavor for this difficult complication, [I wanted to share] some hands-on experience that we have had with narsoplimab outside of the trial with some case studies of patients who have been treated in a compassionate-use basis, said Duarte.

First, Duarte shared a case of a 19-year-old female who received narsoplimab following matched-sibling allogeneic HSCT to treat her B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission.

At 5 months, the patient experienced late-onset acute graft-versus-host disease (GVHD) and severe HSCT-TMA with lower gastrointestinal (GI) bleeding and ischemic ulcers. While skin involvement of GVHD resolved, she received initial treatment with 1 dose of eculizumab (Soliris) due to persistent GI symptoms after steroids, mesenchymal stromal cells, and extracorporeal photopheresis. Additionally, she received 4 mg/kg of narsoplimab once or twice weekly for a total of 18 doses.

We asked for narsoplimab purely on the basis that this was a severely immunocompromised patient who had experienced complications before and who had been receiving a lot of immunosuppression for the treatment of GVHD, said Duarte. We tried to minimize immunosuppression, so we thought narsoplimab would be a good option.

According to Duarte, the patients GI bleeding and microangiopathy hemolytic anemia resolved quickly and dramatically after starting narsoplimab. Additionally, she became transfusion independent with platelet counts above 100 x 109 per liter.

At 21 months, the patient remains in complete remission (CR) of B-ALL and is devoid of signs of HSCT-TMA after discontinuing narsoplimab.

Subsequently, Duarte presented another, more complex case of a 48-year-old male with HIV and Hodgkin lymphoma who was in his third CR.

Following CCR5-32/32 HSCT, the patient experienced very early HSCT-TMA on day 0. Subsequently, he had rapid severe renal failure that required hemodialysis.

Initial treatment with calcineurin inhibitor withdrawal did not elicit any response, so he was started on narsoplimab at 4 mg/kg twice weekly on day 6. He received a total of 8 doses of narsoplimab.

The patients lactate dehydrogenase (LDH), bilirubin, and schistocyte counts improved rapidly following narsoplimab initiation. Additionally, the patient derived partial improvement of renal function and fluid management, although he required continued dialysis.

Despite this, at 31 days post-transplant, the patient had multiple secondary complications as a result of the CCR5-32/32 HSCT and experienced sudden death. The death was not thought to be related to TMA and no autopsy was granted.

We dont have a better explanation regarding what happened with this patient, unfortunately, Duarte explained. We think we are seeing that many of the patients who undergo transplant with this mutated CCR5-32/32 tend to have greater mortality and greater complications than HIV-positive patients who undergo transplant with standard [procedure].

Duarte also presented findings from the pivotal, phase 2 trial, in which narsoplimab demonstrated high rates of CRs, as well as improved laboratory and clinical markers among patients with HSCT-TMA.

Narsoplimab was previously granted a breakthrough therapy designation by the FDA for the treatment of patients with high-risk TA-TMA. In addition, the agent was granted an orphan drug designation for TA-TMA therapy and complement-mediated TMA prevention.

Findings from the single-arm, open-label phase 2 trial demonstrated a 54% CR rate in all treated patients (n = 28) with the mannan-binding lectin-associated serine protease-2 inhibitor (95% CI, 34%-72%). Additionally, patients treated per protocol recommendations (n = 23), which entailed 4 weeks or more of dosing, achieved a CR rate of 65% (95% CI, 43%-84%).

At 100 days following HSCT-TMA diagnosis, 68% of all treated patients, 83% of patients treated per protocol, and 93% of treatment responders (n = 15) were alive.

Eligible patients had to be 18 years of older at screening, which occurred during the patients first visit. Additionally, patients had to have persistent HSCT-TMA as defined by a platelet count less than 150,000 per L, evidence of microangiopathy hemolysis such as the presence of schistocytes, serum LDH greater than upper limit of normal, or haptoglobin less than the lower limit of normal, and renal dysfunction defined as doubling of serum creatinine compared with pre-transplant level. All of the following had to be present for at least 2 weeks following modification or discontinuation of calcineurin inhibitors.

Patients who had eculizumab therapy within 3 months of screening, positive direct Coombs test, or active systemic bacteria or fungal infection that required antimicrobial therapy beyond prophylactic antimicrobial therapy as a standard of care were excluded from the study.

Response-based efficacy requiring improvement in TMA laboratory markers of platelet count and LDH and improvement in clinical status, as well as safety, served as the primary end points of the trial. Secondary end points included survival and change from baseline laboratory markers.

Regarding laboratory markers, LDH had to be less than 1.5 L. For patients who had a baseline platelet count of 20,000/L, improvement was defined as a tripling of baseline platelet count more than 30,000 and freedom from platelet transfusion. For patients with a baseline platelet count of more than 20,000, improvement was defined as an increased count of least 50% and absolute count of more than 75,000, as well as freedom from platelet transfusion.

Clinical improvement was based off any of the following improvements in specific organ function. Patients could derive blood improvement defined as transfusion freedom; renal improvement defined as a reduction of creatinine of more than 40%, normalization of creatinine and more than 20% reduction of creatinine, or discontinuation of renal replacement therapy; pulmonary improvement defined as extubation and discontinuation of ventilator support, or discontinuation of non-invasive mechanical ventilation; gastrointestinal improvement defined as improvement assessed by MAGIC (Mount Sinai GVHD International Consortium) criteria; or neurological improvement defined as limited to stroke, posterior reversible encephalopathy syndrome, seizures, and weakness.

Eligible patients had an average age of 48, and 71% were male. Moreover, 96% of patients had malignant underlying disease. Regarding risk factors, 64% had GVHD, 75% had significant infection, 14% had non-infectious pulmonary complications, such as idiopathy pneumonia syndrome or diffuse alveolar hemorrhage, and 50% had neurological signs.

Moreover, the study population was defined as high risk as 93% of patients had multiple risk factors associated with poor outcome.

Regarding safety, any-grade toxicities were observed in 92.9% of patients treated with narsoplimab. The most common adverse effects (AEs) included nausea, vomiting, diarrhea, hypokalemia, neutropenia, and fever.

Additionally, 21% of patients died while on study; however, all deaths were attributed to common complications of HSCT.

Investigators concluded that similar AEs are associated with patients who undergo transplant and that narsoplimab was generally well tolerated.

These are very highly encouraging results with narsoplimab in patients with very severe TMA who are unresponsive to other treatments. These results suggest that narsoplimab may be of benefit in these severely ill, complex patients with TMA, including those in the most complex clinical scenarios, Duarte concluded.

Reference

Duarte R. MASP-2 inhibition with the investigational agent narsoplimab for the treatment of HSCT-TMA: overview of data and case discussion. Presented at: 2020 European Society for Blood and Marrow Transplantation Annual Meeting; August 30-September 2, 2020; Virtual. Session IS28-4.

Originally posted here:
Emerging Evidence Supports the Use of Narsoplimab in HSCT-TMA - OncLive

Blood cancer survivor who found donor ‘at the eleventh hour’ highlights importance of stem cell donations – Leicestershire Live

Rik Basra was diagnosed with a deadly form of blood cancer in 2009, and then again in 2011.

The father of two was fortunate enough to survive the Acute Myeloid Leukaemia after a last-minute stem cell donor was found in Germany.

The stem cell transplant was successful, which meant the former Leicestershire Police employee could continue to spend time with his family.

Speaking to LeicestershireLive, he detailed his experience and stressed the importance of people joining the donor register.

He said: "I was diagnosed in 2009 originally and was cleared, but then in 2011 it came back.

"The second time I was told that I would need a stem cell transplant and without one I wouldn't make it.

"I had actually finished my last round of chemotherapy and they couldn't give me anymore, because it would have killed me.

"But they managed to find a donor at the 11th hour from someone in Germany."

When the donor was found Rik and his family felt as though all their Christmases had come all at once, he said.

It wasn't a perfect match, but it was enough to give Rik a fighting chance.

After having the stem cell transplant on Christmas Eve in 2011, Rik hasn't had any problems since and says he has got his future back.

"I had been told to make funeral arrangements before that," he said.

"I was shocked and actually I wanted to jump up and down in the air, it was such a surprise.

"Before that, we were just hoping for the best and preparing for the worst.

"We were hoping that some miracle could happen and it did; we got a match. And you have to remember that all those searches had taken place, so this came completely out of the blue."

Want a free daily bulletin - plus breaking news alerts direct to your inbox? Then sign up to our email newsletter service!

All you need to do is type your email address into the 'sign up to free daily alerts' box. It's at the top of this article.

It's also on any stories on the website - simply click 'subscribe' and you can expect your first newsletter at the next release.

Alternatively, click here to sign up online.

Decide later that you no longer wish to receive the emails? No problem - you can just follow the unsubscribe link.

But Rik's situation isn't unique. He said every 14 minutes someone else is diagnosed and in need of the very same stem cell treatment that saved his life.

For some, that match is never found and the arrival of Covid-19 has only reduced the number of people ready and willing to donate.

"It's still really important that people sign up to the register," said Rik.

"Blood cancer doesn't stop for Covid-19.

"You don't have to die to donate your stem cells.

"Anyone could be diagnosed. It's a vested interested for everyone to get involved and do something.

"All the things you take for granted, which were challenging for me, I can now do. It has saved my life and I have got my future back.

"I have two daughters and a granddaughter and I wouldn't have known her and she wouldn't have known me if it wasn't for the donation."

Since his treatment, he has set up Rik Basra Leukaemia Campaign in which he seeks to help people from all different backgrounds join the register and reassures them about any worries they may have.

Anthony Nolan is a charity that works in the areas of leukaemia and hematopoietic stem cell transplantation.

Since the start of the lockdown in March this year, they have seen a huge downfall in the number of donations not just in Leicester but all over the UK.

From March to August 2019, Anthony Nolan held over 300 stem cell donor recruitment events which added over 12,500 donors to the register. Since lockdown in March this year, theyve held zero.

Nearly 19,000 fewer people have joined the stem cell register so far this year compared to the same period in 2019.

In Leicester, between March and August last year, 557 people joined the Anthony Nolan register compared to just 190 between March and August this year.

Henny Braund, chief executive of Anthony Nolan, says: "Unfortunately, the coronavirus pandemic has had a serious impact on our ability to talk to people about the Anthony Nolan register and about their life-saving potential.

"Social distancing restrictions have meant that donor recruitment events have been cancelled and we havent been able to speak to students at schools and universities like we usually would.

"This has resulted in a drop in sign-ups to the register, however transplants continue to happen around the world, which means that we still desperately need people to join the Anthony Nolan register.

"The more people join, the more opportunities are afforded to patients who urgently need treatment. We are particularly calling on young men aged 16-30 to join, as they are the most likely to be chosen to donate."

Joining the register is easy and it can be done online.

If you wish to sign up to the register and help to save lives by donating your stem cells, you can do so by clicking here.

Read the original here:
Blood cancer survivor who found donor 'at the eleventh hour' highlights importance of stem cell donations - Leicestershire Live

Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University | Vaccines…

Details Category: Vaccines Published on Tuesday, 01 September 2020 17:45 Hits: 64

BALTIMORE, MD, USA I September 1, 2020 I Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development and commercialization of therapies for genetic diseases and vaccines, announced that Fujita Health University has received acontract from the Japan Agency for Medical Research and Development (AMED) to initiate Phase I/II clinical trials of the company's COVID-19 vaccine candidate, EXG-5003. Clinical trials are expected to begin at Fujita Health University Hospital in Aichi, Japan in Q1 2021.

EXG-5003 is a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. EXG-5003 was optimized for intradermal injection withpotential dose-sparing and safety benefits.

About Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company, which is focused on curing humanity's ailments through innovations in gene and cell therapy, including stem cell therapy. Elixirgen Therapeutics, Inc. is now applying its RNA technology to the development of a COVID-19 vaccine.For more information visit http://www.ElixirgenTherapeutics.com

About Fujita Health University

Fujita Health University plays a major role in treating COVID-19 patients and conducting its clinical trials in Japan. For more information visit http://www.fujita-hu.ac.jp/en/

SOURCE: Elixirgen Therapeutics

Read the original:
Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University | Vaccines...

How Groups of Cells Cooperate to Build Organs and Organisms – The Scientist

Efforts to use regenerative medicinewhich seeks to address ailments as diverse as birth defects, traumatic injury, aging, degenerative disease, and the disorganized growth of cancerwould be greatly aided by solving one fundamental puzzle: How do cellular collectives orchestrate the building of complex, three-dimensional structures?

While genomes predictably encode the proteins present in cells, a simple molecular parts list does not tell us enough about the anatomical layout or regenerative potential of the body that the cells will work to construct. Genomes are not a blueprint for anatomy, and genome editing is fundamentally limited by the fact that its very hard to infer which genes to tweak, and how, to achieve desired complex anatomical outcomes. Similarly, stem cells generate the building blocks of organs, but the ability to organize specific cell types into a working human hand or eye has been and will be beyond the grasp of direct manipulation for a very long time.

But researchers working in the fields of synthetic morphology and regenerative biophysics are beginning to understand the rules governing the plasticity of organ growth and repair. Rather than micromanaging tasks that are too complex to implement directly at the cellular or molecular level, what if we solved the mystery of how groups of cells cooperate to construct specific multicellular bodies during embryogenesis and regeneration? Perhaps then we could figure out how to motivate cell collectives to build whatever anatomical features we want.

New approaches now allow us to target the processes that implement anatomical decision-making without genetic engineering. In January, using such tools, crafted in my lab at Tufts Universitys Allen Discovery Center and by computer scientists in Josh Bongards lab at the University of Vermont, we were able to create novel living machines, artificial bodies with morphologies and behaviors completely different from the default anatomy of the frog species (Xenopus laevis) whose cells we used. These cells rebooted their multicellularity into a new form, without genomic changes. This represents an extremely exciting sandbox in which bioengineers can play, with the aim of decoding the logic of anatomical and behavioral control, as well as understanding the plasticity of cells and the relationship of genomes to anatomies.

Deciphering how an organism puts itself together is truly an interdisciplinary undertaking.

Deciphering how an organism puts itself together is truly an interdisciplinary undertaking. Resolving the whole picture will involve understanding not only the mechanisms by which cells operate, but also elucidating the computations that cells and groups of cells carry out to orchestrate tissue and organ construction on a whole-body scale. The next generation of advances in this area of research will emerge from the flow of ideas between computer scientists and biologists. Unlocking the full potential of regenerative medicine will require biology to take the journey computer science has already taken, from focusing on the hardwarethe proteins and biochemical pathways that carry out cellular operationsto the physiological software that enables networks of cells to acquire, store, and act on information about organ and indeed whole-body geometry.

In the computer world, this transition from rewiring hardware to reprogramming the information flow by changing the inputs gave rise to the information technology revolution. This shift of perspective could transform biology, allowing scientists to achieve the still-futuristic visions of regenerative medicine. An understanding of how independent, competent agents such as cells cooperate and compete toward robust outcomes, despite noise and changing environmental conditions, would also inform engineering. Swarm robotics, Internet of Things, and even the development of general artificial intelligence will all be enriched by the ability to read out and set the anatomical states toward which cell collectives build, because they share a fundamental underlying problem: how to control the emergent outcomes of systems composed of many interacting units or individuals.

Many types of embryos can regenerate entirely if cut in half, and some species are proficient regenerators as adults. Axolotls (Ambystoma mexicanum) regenerate their limbs, eyes, spinal cords, jaws, and portions of the brain throughout life. Planarian flatworms (class Turbellaria), meanwhile, can regrow absolutely any part of their body; when the animal is cut into pieces, each piece knows exactly whats missing and regenerates to be a perfect, tiny worm.

The remarkable thing is not simply that growth begins after wounding and that various cell types are generated, but that these bodies will grow and remodel until a correct anatomy is complete, and then they stop. How does the system identify the correct target morphology, orchestrate individual cell behaviors to get there, and determine when the job is done? How does it communicate this information to control underlying cell activities?

Several years ago, my lab found that Xenopus tadpoles with their facial organs experimentally mixed up into incorrect positions still have largely normal faces once theyve matured, as the organs move and remodel through unnatural paths. Last year, a colleague at Tufts came to a similar conclusion: the Xenopus genome does not encode a hardwired set of instructions for the movements of different organs during metamorphosis from tadpole to frog, but rather encodes molecular hardware that executes a kind of error minimization loop, comparing the current anatomy to the target frog morphology and working to progressively reduce the difference between them. Once a rough spatial specification of the layout is achieved, that triggers the cessation of further remodeling.

The deep puzzle of how competent agents such as cells work together to pursue goals such as building, remodeling, or repairing a complex organ to a predetermined spec is well illustrated by planaria. Despite having a mechanistic understanding of stem cell specification pathways and axial chemical gradients, scientists really dont know what determines the intricate shape and structure of the flatworms head. It is also unknown how planaria perfectly regenerate the same anatomy, even as their genomes have accrued mutations over eons of somatic inheritance. Because some species of planaria reproduce by fission and regeneration, any mutation that doesnt kill the neoblastthe adult stem cell that gives rise to cells that regenerate new tissueis propagated to the next generation. The worms incredibly messy genome shows evidence of this process, and cells in an individual planarian can have different numbers of chromosomes. Still, fragmented planaria regenerate their body shape with nearly 100 percent anatomical fidelity.

Permanent editing of the encoded target morphology without genomic editing reveals a new kind of epigenetics.

So how do cell groups encode the patterns they build, and how do they know to stop once a target anatomy is achieved? What would happen, for example, if neoblasts from a planarian species with a flat head were transplanted into a worm of a species with a round or triangular head that had the head amputated? Which shape would result from this heterogeneous mixture? To date, none of the high-resolution molecular genetic studies of planaria give any prediction for the results of this experiment, because so far they have all focused on the cellular hardware, not on the logic of the softwareimplemented by chemical, mechanical, and electrical signaling among cellsthat controls large-scale outcomes and enables remodeling to stop when a specific morphology has been achieved.

Understanding how cells and tissues make real-time anatomical decisions is central not only to achieving regenerative outcomes too complex for us to manage directly, but also to solving problems such as cancer. While the view of cancer as a genetic disorder still largely drives clinical approaches, recent literature supports a view of cancer as cells simply not being able to receive the physiological signals that maintain the normally tight controls of anatomical homeostasis. Cut off from these patterning cues, individual cells revert to their ancient unicellular lifestyle and treat the rest of the body as external environment, often to ruinous effect. If we understand the mechanisms that scale single-cell homeostatic setpoints into tissue- and organ-level anatomical goal states and the conditions under which the anatomical error reduction control loop breaks down, we may be able to provide stimuli to gain control of rogue cancer cells without either gene therapy or chemotherapy.

During morphogenesis, cells cooperate to reliably build anatomical structures. Many living systems remodel and regenerate tissues or organs despite considerable damagethat is, they progressively reduce deviations from specific target morphologies, and halt growth and remodeling when those morphologies are achieved. Evolution exploits three modalities to achieve such anatomical homeostasis: biochemical gradients, bioelectric circuits, and biophysical forces. These interact to enable the same large-scale form to arise despite significant perturbations.

N.R. FULLER, SAYO-ART, LLC

BIOCHEMICAL GRADIENTS

The best-known modality concerns diffusible intracellular and extracellular signaling molecules. Gene-regulatory circuits and gradients of biochemicals control cell proliferation, differentiation, and migration.

BIOELECTRIC CIRCUITS

The movement of ions across cell membranes, especially via voltage-gated ion channels and gap junctions, can establish bioelectric circuits that control large-scale resting potential patterns within and among groups of cells. These bioelectric patterns implement long-range coordination, feedback, and memory dynamics across cell fields. They underlie modular morphogenetic decision-making about organ shape and spatial layout by regulating the dynamic redistribution of morphogens and the expression of genes.

BIOMECHANICAL FORCES

Cytoskeletal, adhesion, and motor proteins inside and between cells generate physical forces that in turn control cell behavior. These forces result in large-scale strain fields, which enable cell sheets to move and deform as a coherent unit, and thus execute the folds and bends that shape complex organs.

The software of life, which exploits the laws of physics and computation, is enabled by chemical, mechanical, and electrical signaling across cellular networks. While the chemical and mechanical mechanisms of morphogenesis have long been appreciated by molecular and cell biologists, the role of electrical signaling has largely been overlooked. But the same reprogrammability of neural circuits in the brain that supports learning, memory, and behavioral plasticity applies to all cells, not just neurons. Indeed, bacterial colonies can communicate via ionic currents, with recent research revealing brain-like dynamics in which information is propagated across and stored in a kind of proto-body formed by bacterial biofilms. So it should really come as no surprise that bioelectric signaling is a highly tractable component of morphological outcomes in multicellular organisms.

A few years ago, we studied the electrical dynamics that normally set the size and borders of the nascent Xenopus brain, and built a computer model of this process to shed light on how a range of various brain defects arise from disruptions to this bioelectric signaling. Our model suggested that specific modifications with mRNA or small molecules could restore the endogenous bioelectric patterns back to their correct layout. By using our computational platform to select drugs to open existing ion channels in nascent neural tissue or even a remote body tissue, we were able to prevent and even reverse brain defects caused not only by chemical teratogenscompounds that disrupt embryonic developmentbut by mutations in key neurogenesis genes.

Similarly, we used optogenetics to stimulate electrical activity in various somatic cell types totrigger regeneration of an entire tadpole tailan appendage with spinal cord, muscle, and peripheral innervationand to normalize the behavior of cancer cells in tadpoles strongly expressing human oncogenes such as KRAS mutations. We used a similar approach to trigger posterior regions, such as the gut, to build an entire frog eye. In both the eye and tail cases, the information on how exactly to build these complex structures, and where all the cells should go, did not have to be specified by the experimenter; rather, they arose from the cells themselves. Such findings reveal how ion channel mutations result in numerous human developmental channelopathies, and provide a roadmap for how they may be treated by altering the bioelectric map that tells cells what to build.

We also recently found a striking example of such reprogrammable bioelectrical software in control of regeneration in planaria. In 2011, we discovered that an endogenous electric circuit establishes a pattern of depolarization and hyperpolarization in planarian fragments that regulate the orientation of the anterior-posterior axis to be rebuilt. Last year, we discovered that this circuit controls the gene expressionneeded to build a head or tail within six hours of amputation, and by using molecules that make cell membranes permeable to certain ions to depolarize or hyperpolarize cells, we induced fragments of such worms to give rise to a symmetrical two-headed form, despite their wildtype genomes. Even more shockingly, the worms continued to generate two-headed progeny in additional rounds of cutting with no further manipulation. In further experiments, we demonstrated that briefly reducing gap junction-mediated connectivity between adjacent cells in the bioelectric network that guides regeneration led worms to regenerate head and brain shapes appropriate to other worm species whose lineages split more than 100 million years ago.

My group has developed the use of voltage-sensitive dyes to visualize the bioelectric pattern memory that guides gene expression and cell behavior toward morphogenetic outcomes. Meanwhile, my Allen Center colleagues are using synthetic artificial electric tissues made of human cells and computer models of ion channel activity to understand how electrical dynamics across groups of non-neural cells can set up the voltage patterns that control downstream gene expression, distribution of morphogen molecules, and cell behaviors to orchestrate morphogenesis.

The emerging picture in this field is that anatomical software is highly modulara key property that computer scientists exploit as subroutines and that most likely contributes in large part to biological evolvability and evolutionary plasticity. A simple bioelectric state, whether produced endogenously during development or induced by an experimenter, triggers very complex redistributions of morphogens and gene expression cascades that are needed to build various anatomies. The information stored in the bodys bioelectric circuitscan be permanently rewritten once we understand the dynamics of the biophysical circuits that make the critical morphological decisions. This permanent editing of the encoded target morphology without genomic editing reveals a new kind of epigenetics, information that is stored in a medium other than DNA sequences and chromatin.

Recent work from our group and others has demonstrated that anatomical pattern memories can be rewritten by physiological stimuli and maintained indefinitely without genomic editing. For example, the bioelectric circuit that normally determines head number and location in regenerating planaria can be triggered by brief alterations of ion channel or gap junction activity to alter the animals body plan. Due to the circuits pattern memory, the animals remain in this altered state indefinitely without further stimulation, despite their wildtype genomes. In other words, the pattern to which the cells build after damage can be changed, leading to a target morphology distinct from the genetic default.

N.R. FULLER, SAYO-ART, LLC

First, we soaked a planarian in voltage-sensitive fluorescent dye to observe the bioelectrical pattern across the entire tissue. We then cut the animal to see how this pattern changes in each fragment as it begins to regenerate.

We then applied drugs or used RNA interference to target ion channels or gap junctions in individual cells and thus change the pattern of depolarization/hyperpolarization and cellular connectivity across the whole fragment.

As a result of the disruption of the bodys bioelectric circuits, the planarian regrows with two heads instead of one, or none at all.

When we re-cut the two-headed planarian in plain water, long after the initial drug has left the tissue, the new anatomy persists in subsequent rounds of regeneration.

Cells can clearly build structures that are different from their genomic-default anatomical outcomes. But are cells universal constructors? Could they make anything if only we knew how to motivate them to do it?

The most recent advances in the new field at the intersection of developmental biology and computer science are driven by synthetic living machines known as biobots. Built from multiple interacting cell populations, these engineered machines have applications in disease modeling and drug development, and as sensors that detect and respond to biological signals. We recently tested the plasticity of cells by evolving in silico designs with specific movement and behavior capabilities and used this information to sculpt self-organized growth of aggregated Xenopus skin and muscle cells. In a novel environmentin vitro, as opposed to inside a frog embryoswarms of genetically normal cells were able to reimagine their multicellular form. With minimal sculpting post self-assembly, these cells form Xenobots with structures, movements, and other behaviors quite different from what might be expected if one simply sequenced their genome and identified them as wildtype X. laevis.

These living creations are a powerful platform to assess and model the computations that these cell swarms use to determine what to build. Such insights will help us to understand evolvability of body forms, robustness, and the true relationship between genomes and anatomy, greatly potentiating the impact of genome editing tools and making genomics more predictive for large-scale phenotypes. Moreover, testing regimes of biochemical, biomechanical, and bioelectrical stimuli in these biobots will enable the discovery of optimal stimuli for use in regenerative therapies and bioengineered organ construction. Finally, learning to program highly competent individual builders (cells) toward group-level, goal-driven behaviors (complex anatomies) will significantly advance swarm robotics and help avoid catastrophes of unintended consequences during the inevitable deployment of large numbers of artificial agents with complex behaviors.

Understanding how cells and tissues make real-time anatomical decisions is central to achieving regenerative outcomes too complex for us to manage directly.

The emerging field ofsynthetic morphology emphasizes a conceptual point that has been embraced by computer scientists but thus far resisted by biologists: the hardware-software distinction. In the 1940s, to change a computers behavior, the operator had to literally move wires aroundin other words, she had to directly alter the hardware. The information technology revolution resulted from the realization that certain kinds of hardware are reprogrammable: drastic changes in function could be made at the software level, by changing inputs, not the hardware itself.

In molecular biomedicine, we are still focused largely on manipulating the cellular hardwarethe proteins that each cell can exploit. But evolution has ensured that cellular collectives use this versatile machinery to process information flexibly and implement a wide range of large-scale body shape outcomes. This is biologys software: the memory, plasticity, and reprogrammability of morphogenetic control networks.

The coming decades will be an extremely exciting time for multidisciplinary efforts in developmental physiology, robotics, and basal cognition to understand how individual cells merge together into a collective with global goals not belonging to any individual cell. This will drive the creation of new artificial intelligence platforms based not on copying brain architectures, but on the multiscale problem-solving capacities of cells and tissues. Conversely, the insights of cognitive neurobiology and computer science will give us a completely new window on the information processing and decision-making dynamics in cellular collectives that can very effectively be targeted for transformative regenerative therapies of complex organs.

Michael Levinis the director of the Allen Discovery Center at Tufts University and Associate Faculty at Harvard Universitys Wyss Institute. Email him atmichael.levin@tufts.edu. M.L. thanks Allen Center Deputy DirectorJoshua Finkelsteinfor suggestions on the drafts of this story.

More here:
How Groups of Cells Cooperate to Build Organs and Organisms - The Scientist

Breath to the rescue: COVID-19 is offered to be treated with cellular inhalation – Pledge Times

Scientists from China have proposed treating severe coronavirus pneumonia using cellular technologies. They plan to use exosomes stem cell secretion products as an active component. Experimental studies have shown that their use significantly reduces pneumonia. This technique is safer than injecting the stem cells themselves into the patient, since there is no risk of mutations and cancer development. Another advantage of such therapy is the ability to store drugs for several weeks or even months, which ensures their safe transportation and delayed use. Russian experts believe that the technique looks promising.

Despite the fact that effective methods of treating patients with severe coronavirus infection have already been worked out, many people, especially the elderly and those with poor health, are still at high risk of dying from pneumonia. Therefore, it is imperative to find a safe and effective therapeutic approach for patients with COVID-19 complicated by acute respiratory distress. In this regard, many research teams are turning their attention to the prospect of using human stem cells.

Scientists at the Shanghai Public Health Clinical Center and Jinyintan Hospital in Wuhan plan to launch a pilot study inhalations with stem cell waste products. We are talking about exosomes bubble-like small particles that release all types of cells into the surrounding fluids. They are needed for the intercellular transfer of various proteins or microRNAs. Such exosomes are also secreted by mesenchymal stem cells, which are proposed to be used in the treatment of severe coronavirus pneumonia.

Photo: REUTERS / Richard Chung

Experimental studies have shown that their use significantly reduces lung inflammation and pathological disorders resulting from various types of lung damage, said in the text of the description of the clinical study. At the same time, scientists note that the intravenous administration of living stem cells (not exosomes), which is also now being studied by various scientific teams, can carry the risks of mutations and the development of cancer. What is not observed in the treatment of cells sprayed in an aerosol.

Another advantage of the proposed technique is the possibility of storing such drugs for several weeks and months, which ensures their safe transportation and delayed therapeutic use. As stated in the document, it is planned to recruit 30 participants for the first stage. It is assumed that each will undergo five inhalation procedures.

Mesenchymal stem cells (MSCs) interact with the innate immune system and can have both anti-inflammatory and pro-inflammatory activity. The type of activity is determined by the source of MSC production, surface markers, the profile of secreted cytokines (proteins secreted by immune cells. Izvestia) and other factors, the acting newspaper told the newspaper. Andrei Vasin, director of the Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University (the university is a participant of the 5-100 education competitiveness project).

Since the acute respiratory distress syndrome (ARDS) in COVID-19 is believed to be the result of an imbalance of cytokines and other molecules involved in inflammatory responses, it seems reasonable to use approaches to mitigate these responses. A number of studies have been carried out, which suggested the effectiveness of MSCs for the treatment of ARDS, explained Andrei Vasin. Since some of the functions are realized due to the molecules secreted by these cells, it was proposed to use not them, but exosomes containing these molecules.

Scientists have shown that in some cases the use of exosomes gave the same results as the use of MSCs. Therefore, the stem cells themselves do not need to be injected into the patient. This is the approach that the Chinese researchers decided to use in this clinical study, noted Andrey Vasin. And the very possibility of aerosol administration of the drug potentially has a number of advantages from the point of view of the safety profile and the direction of delivery to the pathology site.

Photo: TASS / Zuma / Xinhua

In general, since the beginning of this year, about two dozen studies have been organized around the world using cellular products, Alexey Lyundup, Executive Director of the Association of BMCP (Biomedical Cell Products) Manufacturers, told Izvestia. Moreover, the sources of cells can be different.

The method proposed by Chinese experts is supposed to use exosomes of adipose tissue MSCs, the expert emphasized. Research continues, the idea itself is promising.

According to the specialist, such exosomes from MSCs contain cytokines and growth factors (natural compounds that can stimulate the production of living cells), signal lipids (substances that transmit signals inside the cell) and other substances necessary to relieve inflammation. However, it is worth waiting for evidence of the safety and effectiveness of their use in preclinical studies. And only then begin clinical trials declared by Chinese scientists.

We have sufficient grounds to believe that mesenchymal stem cells (as well as exosomes with similar properties. Izvestia) extinguish the cytokine storm, said Stanislav Otstavnov, deputy head of the laboratory for analysis of population health indicators and digitalization of healthcare at MIPT. I assess the proposed methodology in China as promising, but clinical trials will tell about the effectiveness and safety. In theory, cell therapy should also help in the regeneration of damaged lung areas, but there is little specific information in official sources on this matter. But the decrease in the immune response has been confirmed.

The experts emphasize that, in general, the available data on the use of exosomes in patients with COVID-19 looks interesting and this approach may be promising. However, so far unanswered questions remain related to the dose of such drugs, the route and frequency of administration, recipient groups, interaction with other treatment methods, and so on. Therefore, research in this direction must be continued.

Visit link:
Breath to the rescue: COVID-19 is offered to be treated with cellular inhalation - Pledge Times

bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D) Gene Therapy for Cerebral…

Details Category: DNA RNA and Cells Published on Sunday, 30 August 2020 13:01 Hits: 463

Long-term results from Phase 2/3 Starbeam study (ALD-102/LTF-304) suggest durability of response post eli-cel with all 20 patients who were free of major functional disabilities (MFDs) at two years (out of 23 evaluable patients) remaining MFD-free through last available follow-up, including all 10 patients who reached at least Year 5 follow-up visit

31 out of 32 patients in ALD-102 had stable Neurologic Function Scores following treatment with eli-cel, including 24 patients with a score of zero as of the last available visit

In clinical studies of eli-cel to date, there have been no reports of graft failure, graft rejection, graft-versus-host disease (GVHD), replication competent lentivirus, or insertional oncogenesis

Company on track to submit Marketing Authorization Application in EU by year-end 2020, and Biologics License Application in U.S. in mid-2021

CAMBRIDGE, MA, USA I August 29, 2020 I bluebird bio, Inc. (Nasdaq: BLUE) announced updated results from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including long-term results from the Phase 2/3 Starbeam study (ALD-102/LTF-304) and data from the Phase 3 ALD-104 study. These data were presented today at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2020), taking place virtually from August 29 - September 1, 2020.

CALD is a fatal neurodegenerative disease primarily affecting young boys. Currently, the only treatment available is allogeneic hematopoietic stem cell transplantation (allo-HSCT), which comes with associated, significant risks, including transplant-related mortality, graft failure or rejection, and graft-versus-host disease (GVHD), said David Davidson, M.D., chief medical officer, bluebird bio. Eighty-seven percent of patients in our Phase 2/3 Starbeam study of eli-cel are alive and free of major functional disabilities (MFDs) at 24 months or more of follow-up. Importantly, there were no reports of graft failure, graft rejection, or GVHD. It is gratifying to see the consistent outcomes with eli-cel and the durability of the treatment effect demonstrated in the children participating in our long-term follow-up study including 10 boys who have now reached at least their Year 5 follow-up visit.

Adrenoleukodystrophy (ALD) is a rare, X-linked metabolic disorder that is estimated to affect one in 21,000 male newborns worldwide. ALD is caused by mutations in the ABCD1 gene that affect the production of adrenoleukodystrophy protein (ALDP) and subsequently cause toxic accumulation of very long-chain fatty acids (VLCFAs) primarily in the adrenal cortex and white matter of the brain and spinal cord.

Approximately 40% of boys with adrenoleukodystrophy will develop CALD, the most severe form of ALD. CALD is a progressive neurodegenerative disease that involves breakdown of myelin, the protective sheath of the nerve cells in the brain that are responsible for thinking and muscle control. Symptoms of CALD usually occur in early childhood and progress rapidly, if untreated, leading to severe loss of neurologic function, and eventual death, in most patients. CALD is associated with six MFDs, which severely compromise a patients ability to function independently: loss of communication, cortical blindness, need for tube feeding, total incontinence, wheelchair dependence, and complete loss of voluntary movement. Nearly half of boys with CALD who do not receive treatment will die within five years of symptom onset.

Patients with CALD experience a rapid decrease in neurologic function after the initial onset of clinical symptoms, so early diagnosis and treatment is critical in order to stop the disease progression and preserve their neurological function. In the Phase 2/3 Starbeam study, 31 of 32 patients had a stable neurologic function score, suggesting that disease progression had stabilized and minimal neurological function was lost, following eli-cel infusion, said Dr. Jrn-Sven Khl, Department of Pediatric Oncology, Hematology and Hemostaseology, Center for Women's and Children's Medicine, University Hospital Leipzig. These results presented at EBMT 2020 are very encouraging and suggest treatment with eli-cel may prevent neurological decline in boys with CALD.

Eli-cel is a one-time investigational gene therapy designed to address the underlying genetic cause of CALD by adding functional copies of the ABCD1 gene into a patients own hematopoietic (blood) stem cells (HSCs) that have been transduced ex vivo with the Lenti-D lentiviral vector (LVV). The addition of a functional gene allows patients to produce the ALDP, which is thought to break down the toxic accumulation of VLCFAs in the brain. There is no need for donor HSCs from another person, as is required for allo-HSCT.

Starbeam Study (ALD-102)/Long-Term Follow-Up Study (LTF-304)

The ALD-102 study has completed enrollment. All reported data below are as of January 2020 and reflect a total population of 32 patients with a median follow-up time of 30.0 months (9.1 70.7 months).

Of the 32 patients who have received eli-cel as of January 2020, 20 have completed ALD-102 and enrolled in a long-term follow-up study (LTF-304). Nine additional patients continue to be followed in ALD-102 and have not reached 24 months post-treatment. As previously reported, two patients withdrew from the study at investigator discretion, and one experienced rapid disease progression early on-study resulting in MFDs and death. To date, 104.3 patient-years of follow-up have been reported for ALD-102 and LTF-304.

The primary efficacy endpoint in the study is the proportion of patients who are alive and free of MFDs at Month 24. Of those patients who have or would have reached Month 24, 87% have met the primary endpoint and continue to be alive and MFD-free at more than two years of follow-up (N=20/23). Fourteen patients have at least four years of follow-up, including 10 patients who have reached at least their Year 5 follow-up visit. The nine patients from ALD-102 that have not reached Month 24 have shown no evidence of MFDs.

Data on several secondary and exploratory efficacy outcomes are reported, including changes in neurologic function score (NFS), a 25-point score used to evaluate the severity of gross neurologic dysfunction across 15 symptoms in six categories; resolution of gadolinium enhancement (GdE), an indicator of active inflammation in the brain; and change in Loes score, an MRI measurement of white matter changes in CALD. Of the 32 patients treated, 31 had stable NFS following treatment with eli-cel, defined as NFS <4, without a change of >3 from baseline, and 24 patients maintained an NFS of 0. An NFS of 0 indicates that there are no concerns with the neurologic functions that are assessed on the 25-point scale. Loes scores generally stabilized within 12-24 months and GdE was no longer seen in most patients following eli-cel treatment.

The primary safety endpoint is the proportion of patients who experience acute (Grade 2) or chronic GvHD by Month 24. GvHD is a condition that may occur after an allo-HSCT, where the donated cells view the recipients body as foreign and attack the body. No events of acute or chronic GvHD have been reported post-eli-cel treatment. There have been no reports of graft failure or graft rejection.

In addition, there have been no cases of replication competent lentivirus or insertional oncogenesis to date. Integration site analysis (ISA) was conducted to determine the pattern of integration post-eli-cel infusion and assess whether dominant or expanding clones were present. In one patient, now enrolled in LTF-304 for long-term follow up, a case of benign clonal expansion was observed with three separate integrations in the DNA of the cell at ACER3, RFX3, and MECOM. As of the patients Month 62 visit in March 2020, the patient remained clinically stable. Bone marrow analyses showed no dysplasia (abnormal cell growth) or molecular abnormalities.

The treatment regimen, comprising mobilization/apheresis, conditioning, and eli-cel infusion, had a safety and tolerability profile primarily reflective of the known effects of mobilization/apheresis and conditioning. In ALD-102, as previously reported, three adverse events (AE) were considered possibly related to drug product and include one serious AE (SAE), BK viral cystitis (N=1, SAE, Grade 3), and two non-serious AEs, vomiting (N=2, Grade 1). All three AEs resolved using standard measures.

ALD-104 Study

bluebird bio is currently enrolling patients for ALD-104, a Phase 3 study designed to assess the efficacy and safety of eli-cel in patients with CALD after myeloablative conditioning using busulfan and fludarabine, a different chemotherapy conditioning regimen than what is used in ALD-102 (busulfan and cyclophosphamide). The primary efficacy endpoint is the proportion of patients who are alive and free of MFDs at Month 24, and the primary safety endpoint is the proportion of patients with neutrophil engraftment after eli-cel infusion. All reported data below are as of February 2020.

In ALD-104, the 13 patients currently on study have a median of 6.1 months of follow-up to date (min-max: 2.2 10.3 months). All 13 patients achieved neutrophil engraftment and 12/13 evaluable patients had platelet engraftment (platelet engraftment pending in one patient as of data cut date). Due to the limited duration of follow-up, only safety data are being presented.

No events of acute or chronic GvHD have been reported and there have been no reports of graft failure, graft rejection, cases of insertional oncogenesis, or replication competent lentivirus.

The treatment regimen, comprising mobilization/apheresis, conditioning, and eli-cel infusion had a safety and tolerability profile primarily reflective of the known effects of mobilization/apheresis and conditioning. In ALD-104, two AEs of pancytopenia were considered possibly related to eli-cel. These two ongoing AEs were deemed as suspected unexpected serious adverse reactions (SUSARs) by the principal investigator and were diagnosed approximately two months post-eli-cel infusion in two patients (one Grade 2 and one Grade 3). An additional AE was ongoing as of February 2020, a Grade 3 SAE of transverse myelitis that was diagnosed in the presence of viral infection (adenovirus and rhinovirus/enterovirus positivity) approximately six months after eli-cel infusion and deemed unrelated to eli-cel.

eli-cel Presentation at EBMT

Lenti-D hematopoietic stem cell gene therapy stabilizes neurologic function in boys with cerebral adrenoleukodystrophy

Presenting Author: Dr. Jrn-Sven Khl, Department of Pediatric Oncology, Hematology and Hemostaseology, Center for Women's and Children's Medicine, University Hospital Leipzig Poster Session & Number: Gene Therapy; ePoster O077

Presentations will be available for virtual viewing throughout the duration of the live meeting on the EBMT 2020 website and content will be accessible online following the close of the meeting until November 1, 2020.

About elivaldogene autotemcel (eli-cel, formerly Lenti-D)

In July 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted an accelerated assessment to eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD). bluebird bio is currently on track to submit the Marketing Authorization Application (MAA) in the EU for eli-cel for CALD by year-end 2020, and the Biologics License Application (BLA) in the U.S. in mid-2021.

bluebird bio is currently enrolling patients for a Phase 3 study (ALD-104) designed to assess the efficacy and safety of eli-cel after myeloablative conditioning using busulfan and fludarabine in patients with CALD. Contact This email address is being protected from spambots. You need JavaScript enabled to view it. for more information and a list of study sites.

Additionally, bluebird bio is conducting a long-term safety and efficacy follow-up study (LTF-304) for patients who have been treated with eli-cel for CALD and completed two years of follow-up in bluebird bio-sponsored studies.

The Phase 2/3 Starbeam study (ALD-102) has completed enrollment.

For more information about bluebird bio-sponsored studies visit: http://www.bluebirdbio.com/our-science/clinical-trialsor clinicaltrials.gov.

The European Medicines Agency (EMA) accepted eli-cel gene therapy for the treatment of CALD into its Priorities Medicines scheme (PRIME) in July 2018, and previously granted Orphan Medicinal Product designation to eli-cel.

The U.S. Food and Drug Administration (FDA) granted eli-cel Orphan Drug status, Rare Pediatric Disease designation, and Breakthrough Therapy designation for the treatment of CALD.

Eli-cel is not approved for any indication in any geography.

About CALD Early Diagnosis

Early diagnosis of CALD is important, as the outcome of available treatment varies with the clinical stage of the disease. Newborn screening for ALD is a critical enabler of early diagnosis and thus of successful treatment of ALD. Once a patient has been diagnosed with ALD, regular MRI scans are critical to detect white matter changes indicative of progression to CALD.

In the U.S., newborn screening for ALD was added to the Recommended Universal Screening Panel in February 2016 and is currently active in 17 states, accounting for > 58 percent of U.S. newborns. Outside the U.S., the Minister of Health in the Netherlands has approved the addition of ALD to their newborn screening program. Even though ALD newborn screening has not been implemented in most EU countries, efforts to begin pilot programs are slowly progressing.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders including cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

SOURCE: bluebird bio

See original here:
bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D) Gene Therapy for Cerebral...

Stem Cell Therapy Market Size, Overview, Key Players, Regional Demand, Trends and Forecast to 2027 – Scientect

New Jersey, United States,- The Stem Cell Therapy Market research report 2020-2027 is a historical overview and an in-depth study of the current and future markets of the Stem Cell Therapy industry. The report provides a basic overview of Stem Cell Therapy market size, status, and competitive segment with a basic introduction of major vendors, major regions, product types and end industries. This report provides a historical overview of Stem Cell Therapy market trends, growth, revenue, capacity, cost structure, and key driver analysis.

The Stem Cell Therapy Market report is a compilation of key development trends defining the growth of the industry in terms of geographic scope and competitive scenario. It also highlights the challenges and constraints that affect the business case and provides data on the opportunities that will increase industry compensation. In addition, the study consists of an impact analysis of the coronavirus outbreak in order to provide a comprehensive view of the market outlook for the coming years.

This report studies the Stem Cell Therapy market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in Stem Cell Therapy industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Stem Cell Therapy industry.

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate for each application.

Stem Cell Therapy Market Segmentation:

In market segmentation by types of Stem Cell Therapy, the report covers-

In market segmentation by applications of the Stem Cell Therapy, the report covers the following uses-

Some of Top Market Players Analysis Included in this Report:

Competitive Analysis

Stem Cell Therapy market is highly fragmented, and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cell Therapy market for Global, Europe, North America, Asia-Pacific and South America.

This comprehensive report will provide:

Opportunities in the Stem Cell Therapy Market report

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Key reason to Purchase the report

Customization of the Report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read the original:
Stem Cell Therapy Market Size, Overview, Key Players, Regional Demand, Trends and Forecast to 2027 - Scientect

CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL – PRNewswire

SUZHOU, China, Aug. 30, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", HKEX: 2616) today announced that the US Food and Drug Administration (FDA) has completed their review of the Investigational New Drug (IND) application for anti-PD-L1 monoclonal antibody sugemalimab (CS1001) monotherapy in the relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) with study may proceed (SMP) letter received.

Sugemalimab is an investigational fully human, full-length anti-PD-L1 monoclonal antibody developed by CStone. Compared with other drugs of the same class, sugemalimab has a lower risk of immunogenicity and potential toxicities in patients. CS1001-201 is a single-arm, multicenter pivotal Phase II clinical study designed to evaluate sugemalimab monotherapy in R/R ENKTL. The IND clearance indicates that the ongoing CS1001-201 study in China will be extended to the US.

ENKTL is a subtype of mature T cell and NK cell lymphoma. Epidemiology of the disease is characterized by higher incidence rates in Asia than in Europe or North America. In China, ENKTL accounts for approximately 6% of all lymphoma cases[1]. R/R ENKTL is highly malignant and aggressive, and has a poor prognosis. Patients with R/R ENKTL lack effective salvage treatments if standard L-asparaginase-based regimens fail, and do not respond well to traditional treatments. For these patients, clinicians almost run out of treatment choices because the disease progresses rapidly with an extremely short overall survival (OS) as indicated by historically reported 1-year OS rate <20%[2]. The currently approved targeted monotherapy in China has a complete response (CR) rate of approximately 6%[3],[4]. There are vast unmet medical needs in this patient population of which the first-line treatment has failed. Sugemalimab is expected to provide new treatment options for these patients.

Dr. Jason Yang, Chief Medical Officer of CStone, commented: "For the treatment of ENKTL, CR rate is a critical outcome measure. Data reported for CS1001-201 study on 2019 ASH meeting shows that sugemalimab demonstrated a CR rate of 33.3% with a durable response, an objective response rate (ORR) of 43.3%, and 1-year OS rate of 72.4%. These results represent a major breakthrough compared to current treatment options and support sugemalimab as a potential conditioning regimen for hematopoietic stem cell transplantation. We will work closely with the US FDA and the National Medical Products Administration (NMPA), to bring sugemalimab to R/R ENKTL patients worldwide soon."

Overview of the CS1001-201 trial

CS1001-201 is a single-arm, multicenter Phase II clinical study designed to evaluate sugemalimab monotherapy in R/R ENKTL. The primary endpoint of the trial is ORR assessed by an independent radiological review committee.

According to updated results reported at the 2019 American Society of Hematology (ASH) Annual Meeting, as of October 8, 2019, a total of 32 patients with R/R ENKTL were enrolled in the study. All patients received sugemalimab 1200 mg intravenously every 3 weeks until disease progression or intolerable toxicity. The median duration of follow-up was 6.54 months (range, 0.7215.64).

Preliminary efficacy data

Sugemalimab demonstrated robust efficacy with a high CR rate and durable response in R/R ENKTL patients:

Safety data

Sugemalimab was well tolerated in patients with R/R ENKTL:

About Sugemalimab

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by the U.S.-based Ligand Corporation, sugemalimab is developed by the OmniRat transgenic animal platform, which can generate fully human antibodies in one stop. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody, which can reduce the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs.

Sugemalimab has completed a Phase I dose-escalation study in China. During Phase 1a and 1b stages of the study, sugemalimab showed good antitumor activity and good tolerability in multiple tumor types.

Currently, sugemalimab is being investigated in a number of ongoing clinical trials. In addition to a Phase I bridging study in the U.S., the clinical program in China includes one multi-arm Phase Ib study for several tumor types, one Phase II registrational study for lymphoma, and four Phase III registrational studies, respectively, for stage III/IV NSCLC, gastric cancer, and esophageal cancer.

About CStone

CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Forward-looking Statement

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

[1], , , , . 10002. . 2012;11(2):111-115.

[2] Bellei M, et al., The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103(7):1191-1197.

[3] Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766-1771.

[4] Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.

SOURCE CStone Pharmaceuticals

http://www.cstonepharma.com

View original post here:
CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL - PRNewswire